Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pin-Nan Cheng

Showing results (31-40 of 137) with videos related to

Pageof 14
Sort By:
Life (Basel, Switzerland)|October 28, 2023
Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and TreatmentWei-Chu Tsai, Hseuh-Chien Chiang, Yen-Cheng Chiu, et al.
Journal of Medical Virology|February 18, 2011
Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agentsPin-Nan Cheng, Wen-Chun Liu, Hung-Wen Tsai, et al.
Journal of Viral Hepatitis|September 15, 2020
Persistent augmentation of central arterial stiffness following viral clearance by direct-acting antivirals in chronic hepatitis CJu-Yi Chen, Pin-Nan Cheng, Yen-Cheng Chiu, et al.
Microorganisms|June 2, 2021
Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg LossI-Chin Wu, Wen-Chun Liu, Yen-Cheng Chiu, et al.
Gut|June 16, 2017
Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infectionHung-Yu Sun, Pin-Nan Cheng, Chiung-Ying Tseng, et al.
Journal of Gastroenterology and Hepatology|August 25, 2019
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in TaiwanJyh-Jou Chen, Pei-Lun Lee, Hung-Chih Chiu, et al.
Environmental Health and Preventive Medicine|February 12, 2024
Non-linear association between long-term air pollution exposure and risk of metabolic dysfunction-associated steatotic liver diseaseWei-Chun Cheng, Pei-Yi Wong, Chih-Da Wu, et al.
Hepato-Gastroenterology|May 17, 2003
High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis CPin-Nan Cheng, Chung-Min Jen, Kung-Chia Young, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 4, 2009
Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2bKuo-Chih Tseng, Li-Hsuan Chen, Chi-Yi Chen, et al.
Hepato-Gastroenterology|July 23, 2009
HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapyKuo-Chih Tseng, Pin-Nan Cheng, I-Chin Wu, et al.
Pageof 14

Showing results (31-40 of 137) with videos related to

Sort By:
Pageof 14
Life (Basel, Switzerland)|October 28, 2023
Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and TreatmentWei-Chu Tsai, Hseuh-Chien Chiang, Yen-Cheng Chiu, et al.
Journal of Medical Virology|February 18, 2011
Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agentsPin-Nan Cheng, Wen-Chun Liu, Hung-Wen Tsai, et al.
Journal of Viral Hepatitis|September 15, 2020
Persistent augmentation of central arterial stiffness following viral clearance by direct-acting antivirals in chronic hepatitis CJu-Yi Chen, Pin-Nan Cheng, Yen-Cheng Chiu, et al.
Microorganisms|June 2, 2021
Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg LossI-Chin Wu, Wen-Chun Liu, Yen-Cheng Chiu, et al.
Gut|June 16, 2017
Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infectionHung-Yu Sun, Pin-Nan Cheng, Chiung-Ying Tseng, et al.
Journal of Gastroenterology and Hepatology|August 25, 2019
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in TaiwanJyh-Jou Chen, Pei-Lun Lee, Hung-Chih Chiu, et al.
Environmental Health and Preventive Medicine|February 12, 2024
Non-linear association between long-term air pollution exposure and risk of metabolic dysfunction-associated steatotic liver diseaseWei-Chun Cheng, Pei-Yi Wong, Chih-Da Wu, et al.
Hepato-Gastroenterology|May 17, 2003
High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis CPin-Nan Cheng, Chung-Min Jen, Kung-Chia Young, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 4, 2009
Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2bKuo-Chih Tseng, Li-Hsuan Chen, Chi-Yi Chen, et al.
Hepato-Gastroenterology|July 23, 2009
HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapyKuo-Chih Tseng, Pin-Nan Cheng, I-Chin Wu, et al.
Pageof 14